Diabetes & Metabolism

Papers
(The H4-Index of Diabetes & Metabolism is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Contents - page 178
Diuretics and risk of major adverse limb events in patients with type-2 diabetes: An observational retrospective study67
Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial67
Analysis of glycemic control in diabetic patients by monitoring HbA1c levels before, during and after Covid-19 confinement in Auvergne, France61
Editorial board45
SGLT2 inhibitors and the autonomic nervous system in diabetes: A promising challenge to better understand multiple target improvement43
Discontinuation of hemodialysis after correction of a major hypothyroidism episode, A case report42
Cost analysis of continuous glucose monitoring in patients hospitalized in a diabetes department39
Editorial board35
Contents35
Early life Bacillus Calmette-Guerin vaccination and incidence of type 1, type 2, and latent autoimmune diabetes in adulthood33
Association of diabetes and outcomes in patients with COVID-19: Propensity score-matched analyses from a French retrospective cohort31
Prevalence and incidence of cardiovascular and renal diseases in type 1 compared with type 2 diabetes: A nationwide French observational study of hospitalized patients30
Association between adipose deposition and mortality among adults without major cardiovascular risk factors30
Comment on “Elevated triglyceride–glucose index predicts risk of incident ischemic stroke: The Rural Chinese cohort study”29
Eleven-year trends in socioeconomic inequalities in the prevalence and incidence of pharmacologically treated type 2 diabetes in France, 2010–202029
Associations of young onset age and genetic risk of beta cell dysfunction with glycaemic progression in individuals with type 2 diabetes29
Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review28
Concise review of lipidomics in nonalcoholic fatty liver disease28
Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19?28
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes27
Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis26
Obesity rather than diabetes impacted severe Covid-19 on reunion island: A retrospective cohort study from a frontline hospital, 2020–202126
Contents24
Sommaire24
Effects of SGLT2 inhibitors on clinical cancer survival in patients with type 2 diabetes24
Editorial board24
Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes24
0.075237989425659